by O'Hare on June 17, 2013
Paul Etzer, BioOhio member from the professional services firm Skoda, Minotti’s and long-time fixture in Ohio’s bioscience scene switches gears – efficiently, of course. He discusses the state of sustainable business operations, particularly relating to building construction and management. Would it display business savvy to create a new bioscience space that was not green? Doesn’t sound like it. See the blog posting from Crain’s Cleveland Business.
Have a story to share about how your bioscience operation is responding (or not, by design or circumstance) to the “green” imperative? We love to hear from you – drop us a line.
by O'Hare on June 13, 2013
The Cleveland Biomedical Online Job Fair will feature 35 employers that are seeking candidates to fill over 300 open positions in bioscience and biomedical positions. The Job Fair opens on June 17th at 9AM.
Those interested in participating are encouraged to register prior to the event in order to more efficiently explore opportunities.
Here’s the link and a wish for a successful career exploration. . .
by O'Hare on June 9, 2013
Robert J. Schuellein was one of the founding members of the University of Dayton’s Biology department. Even after his death in 2011, his legacy will live on due to the his many professional accomplishment, first at the University and later at the National Institutes of Health.
And owing to a large gift to the university that was set up by Dr. Schuellein in 1998, his legacy will in the form of many programs and improvements that will be made possible by his generosity.
See story from the University of Dayton website.
by O'Hare on June 6, 2013
The International Neuromodulation Society’s 11th World Congress will take place in Berlin, Germany from June 8-13, and Cleveland, OH-based Neuros Medical plans to draw positive attention. After the completion of a long term pilot study, Neuros will announce significant positive results from use of a medical device it has under development. Chief findings from the study are expected to include no demonstrated safety issues, an 83% reduction in pain, and a reduction in pain narcotic usage for patients suffering from chronic amputation pain.
See the full news release
